Category: Business

Wattbike acquisition is the latest milestone in transformational strategy and the Sportstech acquisition is on track to close in the third quarter

TRNR confirms guidance of more than $75 million in pro forma 2025 revenue and profitability in fourth quarter

TRNR’s $55 million Digital Asset Treasury is actively purchasing $FET cryptocurrency

AUSTIN, TX AND NOTTINGHAM, UK / ACCESS Newswire / July 1, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the CLMBR and FORME brands and pending acquirer of Sportstech, today announced that it has completed its previously announced all-stock acquisition of Wattbike, the pioneering indoor performance training bike business trusted by elite athletes and fitness enthusiasts worldwide, which has cumulatively sold more than 100,000 bikes.

The closing follows the approval on June 18, 2025 from the UK Financial Conduct Authority and the satisfaction of all material conditions of the binding transaction agreement signed in April 2025. Wattbike’s operations will be consolidated into TRNR’s results immediately and will be reported in TRNR’s third quarter financials.

“Today’s acquisition marks the latest milestone in the transformational strategy that we have outlined to investors and should provide increased confidence in our ability to execute against our plan,” said Trent Ward, Co-Founder & Chief Executive Officer of TRNR. “Wattbike is now officially part of TRNR, and we look forward to being able to announce the completion of the Sportstech acquisition in the near-term.

Mr. Ward continued: “As a result of those transactions, we expect to generate more than $75 million of pro forma 2025 revenue and achieve profitability in the fourth quarter. When combined with the $55 million we raised a few weeks ago for our innovative Digital Asset Treasury strategy, and the fact that we are actively investing in AI-focused $FET, we believe that TRNR has significant, under-appreciated upside.”

Mr. Ward concluded: “Wattbike’s operations, thousands of customer gyms and world-class brand give us meaningful assets and scale in the world’s second-largest fitness market – the UK. Its differentiated range of products – for both elite and mainstream athletes – also create big potential opportunities in the US, EU and Asia.”

Stephen Loftus, CEO of Wattbike, added: “TRNR’s unique portfolio of operating assets, combined with its Nasdaq listing, and increasing focus on using cost-effective technology is expected to unlock new levels of growth for Wattbike. We’re thrilled to start building the next chapter together.”

Recap – Transaction highlights:

• Creates a diversified connected hardware portfolio spanning cycling (Wattbike), vertical climbing (CLMBR) and digital strength (FORME).

In terms of next steps, TRNR anticipates continuing with integration planning and execution, including optimizing the global distribution networks and channels it already shares with Wattbike – e.g., with entities like Woodway – as well as its manufacturing and supply chain partnerships to drive rapid cost synergies and working-capital optimization.

In addition, joint teams are already working on ways to leverage Wattbike’s uniquely differentiated dataset on performance training, including with AI-focused training experiences developed with Fetch.ai and powered by TRNR’s recently announced up to $500 million $FET Digital Asset Treasury strategy. Finally, the Sportstech acquisition remains on track to close in the third quarter.

View the original press release on ACCESS Newswire

HOUSTON, TEXAS / ACCESS Newswire / July 1, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with 20,000 leasehold acres comprising two fields in the Permian Basin in southeast New Mexico. Today, the Company reports that the management team and independent directors (“Team”) bought a combined 301,000 shares of the Company’s Class A Common Stock on the open market.

“The Team, during a short window between the announcement of the South Justis Field acquisition and the quarter-end black-out period, was able to buy a significant number of shares,” said Mitchell B. Trotter, CFO of the Company.

Dante Caravaggio, President and CEO of the Company, stated that “We have two major projected events, previously announced, that make a step change for EON. The first is the Enstream funding of $52 million to pay off the agreement with the Seller, to pay off our senior debt, and to fund $9.5 million in oil well workovers. Combined, these actions dramatically change our balance sheet and oil production. The second major event is the selection of a drilling partner who will bring potentially $50 to $100 million in funding to develop our tremendous San Andres reserves. Both events are forecasted to close in August; however, there is no assurance that we will do so. Clearly the EON management team is optimistic.”

About the Grayburg-Jackson Oil Field Property

LH Operating, LLC (“LHO”), a wholly owned subsidiary of EON, operates its holdings in New Mexico of oil and gas waterflood production comprising 13,700 contiguous leasehold acres, 342 producing wells and 207 injection wells situated on 20 federal and 3 state leases in the Grayburg-Jackson Oil Field. The Grayburg-Jackson Oil Field is located on the Northwest Shelf of the prolific Permian Basin in Eddy County, New Mexico.

Leasehold rights of LHO include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2024 reserve report from our third-party engineer, Haas and Cobb Petroleum Consultants, LLC (“Haas & Cobb” or “Cobb”), reflects LHO to have proven reserves of approximately 14.0 million barrels of oil and 2.8 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) in the LHO leasehold is approximately 876 million barrels of oil in the Grayburg and San Andres intervals and 80 million barrels in the Seven Rivers interval for a total OOIP of approximately 956,000,000 barrels of oil.

Our primary production is currently from the Seven Rivers zone. In addition to proven reserves, the Company believes it may access an additional 34 million barrels of oil by adding perforations in the Grayburg and San Andres formations. With proven oil reserves of over 15 million barrels, combined with the potential 34 million additional barrels from the Grayburg and San Andres zones, LHO should produce oil and a revenue stream for more than two decades with a low decline rate.

About the South Justis Field Property

The South Justis Field (“SJF” or “Field”) is a carbonate reservoir, similar to the rest of the Permian. The Field was first developed in the 1960’s and had an initial production in the 6,000 BOPD range. The waterflood implemented at a cost of $40 million dollars in the 1990’s by a major oil company. The subsequent owners of the Field had higher priorities, which led to an increase in idle wells with downhole failures, thus allowing the production to drop dramatically. The Seller acquired the field and has reactivated several wells and increased the production of oil.

The SJF comprises of 5,360 contiguous acres with 208 combined producing and injection wells with large spacing of 50 acres. The field is located in the Central Basin of the prolific Permian Basin in Lea County, New Mexico located approximately 100 miles from EON’s Grayburg-Jackson Oil Field property. The rights include the Glorietta, Blinebry, Tubb, Drinkard and Fusselman intervals that range from 5,000 feet to 7,000 feet in depth. The original-oil-in-place (“OOIP”) is approximately 207 million barrels of oil.

About EON Resources Inc.

EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. EON’s long-term goal is to maximize total shareholder value from a diversified portfolio of long-life oil and natural gas properties built through acquisition and through selective development, production enhancement, and other exploitation efforts on its oil and natural gas properties.

EON’s Class A Common Stock trades on the NYSE American Stock Exchange (NYSE American: EONR) and the Company’s public warrants trade on the NYSE American Stock Exchange (NYSE American: EONR WS). For more information on EON, please visit the Company’s website: https://www.eon-r.com/

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations
Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire

Geophysics Survey Reveals Striking Similarities to World-Class Mountain Pass Rare Earth Deposit;

Geochemical Anomalies Bolster Exploration Potential

SAN BERNARDINO, CA / ACCESS Newswire / July 1, 2025 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF) (“Dateline” or “the Company”) is thrilled to announce the successful completion of a comprehensive magnetotelluric (MT) geophysical survey at its 100%-owned Colosseum Gold-REE Project, located in East San Bernardino County, California. The survey, finalized on June 29, 2025, with 167 stations surveyed across a 200-meter line spacing and 150-meter station spacing grid, has yielded preliminary data that closely aligns with the geophysical signature of the world-class Mountain Pass rare earth element (REE) deposit, situated just 10 km to the south. Concurrently, the ongoing geochemical sampling program is 75% complete, with initial assay results confirming anomalous REE concentrations, further enhancing the project’s exploration prospects.

Key Findings

• Geochemical Sampling Progress: As of June 30, 2025, 916 of approximately 1,200 soil and rock samples have been collected on a 60-meter spaced grid across the claim block, representing 75% completion. Initial assays from the first batch, processed by ALS Global Laboratories in Reno, Nevada, using aqua regia super trace ICP-MS analysis, have detected anomalous REE values, including cerium, lanthanum, and yttrium, above background levels. The program is on track for completion by mid-July, with full results expected later that month.

Detailed Survey Insights

The preliminary 2D resistivity section for line 2200N highlights a near-surface high-resistivity anomaly directly overlying fenite and trachyte dykes, which are exposed in the Colosseum pit walls and mapped north and east of the breccia pipes. This spatial correlation suggests a deep-seated resistive body, potentially a carbonatite intrusion, associated with REE mineralization. Across other survey lines, distinct resistivity contrasts indicate clay-rich alteration zones (low resistivity), possibly linked to gold-bearing breccia pipes, and higher-resistivity zones that may reflect unaltered intrusive or silicified areas. These findings align with Dateline’s goal of imaging deep structures and alteration zones, with all preliminary sections under review by the technical team.

Mountain Pass Geophysical Benchmark

The Mountain Pass deposit, operated by MP Materials, provides a proven geophysical template for Colosseum. According to USGS studies (Peacock et al., 2021), Mountain Pass’s carbonatite orebody exhibits a dense, non-magnetic core surrounded by moderately resistive host rocks. At Colosseum, the fenite-bearing zone on line 2200N corresponds with a gravity high from the 2024 survey, a magnetic low from regional datasets, and the observed intermediate resistivity. This trifecta of anomalies, consistent with carbonatite REE systems, positions Colosseum as a high-potential exploration target. The Company is integrating these findings with historical data to refine the exploration model.

Geochemical Sampling Update

The geochemical program, initiated in mid-June 2025, involves systematic sampling across the entire claim block, with crews collecting 0.5 kg of material per sample using GPS-guided 60-meter spacing. Samples are dried, crushed, split, and pulverized at ALS Global, with assays targeting gold, silver, REEs, and pathfinder elements. The initial results, showing REE anomalies, are a critical early indicator of mineralization. Once all 1,200 samples are assayed, Dateline will generate geochemical anomaly maps to identify multi-element clusters, integrating these with geophysical data to prioritize drill targets.

Next Steps

Dateline is transitioning to the data integration and target definition phase, with the following planned activities:

Integrated Targeting and Drill Program: The 3D MT model, complete geochemical dataset, and reprocessed gravity/magnetic data will be layered to identify coincident anomalies. High-priority targets exhibiting the Mountain Pass-like signature (gravity high, magnetic low, intermediate resistivity) will be slated for drilling. The planned campaign will test both REE potential in the carbonatite target and remaining gold resources in the breccia pipes, with updates to follow upon target finalization.

About Dateline Resources Limited

Dateline Resources Limited (ASX: DTR, OTCQB: DTREF) is an Australian company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in California.

The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.

On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.
The Colosseum is located less than 10km north of the Mountain Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.

Forward-Looking Statements

This announcement may contain “forward-looking statements” concerning Dateline Resources that are subject to risks and uncertainties. Generally, the words “will”, “may”, “should”, “continue”, “believes”, “expects”, “intends”, “anticipates” or similar expressions identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Dateline Resources’ ability to control or estimate precisely, such as future market conditions, changes in regulatory environment and the behavior of other market participants. Dateline Resources cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements. Dateline Resources assumes no obligation and does not undertake any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except to the extent legally required.

Competent Person Statement

Sample preparation and any exploration information in this announcement is based upon work reviewed by Mr Greg Hall who is a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM). Mr Hall has sufficient experience that is relevant to the style of mineralization and type of deposit under consideration and to the activity which he is undertaking to quality as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting Exploration Results, Mineral Resources and Ore Reserves” (JORC Code). Mr Hall is a Non-Executive Director of Dateline Resources Limited and consents to the inclusion in the report of the matters based on this information in the form and context in which it appears.

Contact Information


Stephen Baghdadi

Managing Director

Dateline Resources Limited

+61 2 9375 2353

info@datelineresources.com.au

www.datelineresources.com.au

Andrew Rowell

White Noise Communications

+61 400 466 226

andrew@whitenoisecomms.com
Follow Dateline on X: @Dateline_DTR

Dateline Resources Limited

Level 29, 2 Chifley Square, Sydney,
NSW 2000, Australia

This press release is authorized for release by the Board of Dateline Resources Limited.

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

Signed Partnership Agreement with Long-Term Framework to Support Go-to-Market Plan, Regulatory Progress, and Customer Acquisition Strategy

NEW YORK, NY AND DALLAS, TX / ACCESS Newswire / July 1, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (Nasdaq: GSRT), a publicly traded special purpose acquisition company, today announced that Terra Innovatum has signed a Memorandum of Understanding (“MOU”) with TechSource Inc., an employee-owned science and engineering firm specializing in end-to-end nuclear energy and weapons lifecycle management, advanced scientific R&D, and leadership in the delivery of cutting edge solutions across the federal and commercial sectors. In this partnership TechSource will accelerate the introduction of Terra Innovatum’s SOLO™ micro-modular reactor through supply chain and regulatory advisory support, while expanding access to potential strategic investors, customers and U.S. agency funding programs, including deployment pathways at the U.S. Department of Energy (“DOE”) and Department of Defense (“DOD”).

“This collaboration represents a pivotal milestone in advancing our SOLO™ MMR technology toward full-scale commercialization,” said Alessandro Petruzzi, Co-founder & CEO of Terra Innovatum. “TechSource’s deep network across U.S. governmental agencies, expertise in nuclear material management and U.S. regulatory knowledge will support our regulatory and commercial progress, while bolstering our federal funding and customer acquisition opportunities. Together, we plan to strengthen our connection with industry leaders and national laboratories in the U.S. to build a foundation for the widespread deployment of safe, modular nuclear power. Together, we are fast-tracking SOLO™’s impact on a cleaner, more resilient global energy future.”

“TechSource is proud to partner with Terra Innovatum at this critical inflection point for advanced nuclear innovation,” said V. Brian D’Andrea, Chairman & CEO of TechSource. “Our involvement with nuclear reactor technology dates back to our company’s inception and carries through to today. With decades of experience supporting the Department of Energy, the Department of Defense, national laboratories, and public-sector institutions, we are uniquely positioned to help accelerate the commercialization and deployment of the SOLO™ micro-modular reactor. This collaboration underscores our shared commitment to strengthening national security, advancing safe, scalable nuclear technologies that drive energy resilience, , and delivering technically challenging solution sets across both domestic and international markets.”

Giordano Morichi, Partner, Chief Business Development Officer & Investor Relations of Terra Innovatum stated: “This agreement marks a pivotal step in accelerating the commercial deployment of our technology. TechSource’s unmatched track-record, combined with their expertise in regulatory strategy, stakeholder engagement, and national program execution, makes them an invaluable partner as we bring SOLO™ to market. Together, we’re building not just a deployment plan, but a go-to-market strategy that integrates site development, government partnerships, and industrial adoption. This MOU sets the stage for unlocking real-world opportunities that will move our technology from design to large-scale commercial impact.”

Curtis Christensen, Senior Vice President, West Operations at TechSource, concluded: “This partnership is a natural alignment of vision and capability. Terra Innovatum is pushing the frontier of modular nuclear innovation, and TechSource brings decades of experience delivering complex nuclear programs for federal agencies and international partners. Together, we can accelerate SOLO™’s journey from concept to deployment. Our team is committed to supporting the full lifecycle of this technology-from regulatory approval and site development to stakeholder engagement and long-term operations. We see SOLO™ not just as a reactor, but as a transformative energy solution for critical infrastructure, defense applications, and the global clean energy transition.”

In Picture: A conceptual rendering showcasing four SOLO™ micro-modular reactors (4 MWe / 20 MWt) seamlessly integrated into an off-grid military complex-highlighting the system’s compact footprint, scalability, and potential to deliver clean, reliable power directly at the point of use.

Under the terms of the agreement, Terra Innovatum and TechSource Inc. will work collaboratively on identifying and securing optimal sites for reactor assembly and deployment, optimize supply chain management, support NRC compliance, and engage with key stakeholders-including the DOE, DOD, international laboratories, industry leaders, and institutional end users. The collaboration also paves the way for potential co-investments in operational hubs, advanced manufacturing infrastructure, and strategic R&D partnerships.

ABOUT TERRA INNOVATUM & SOLO^TM

Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 Mwe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: www.terrainnovatum.com.

ABOUT TECHSOURCE INC

Founded in 1997, TechSource is a recognized leader in nuclear science and engineering, comprising more than 500 senior-level scientists, engineers, and industry experts drawn from national laboratories, federal technology programs, and the nuclear industry. The company is widely regarded as an independent, qualified expert, with its advice and solutions trusted as authoritative by clients and their stakeholders.

TechSource consultants bring decades of hands-on experience across the full spectrum of the nuclear material life cycle, including basic and materials research, facility design and operations, weapons programs, material disposition, and systems and operations analysis. Their deep expertise spans particle accelerator design and operation, nuclear power generation, nuclear materials technology, national laboratory initiatives, enterprise and operational IT programs, and complex systems integration.

To learn more, visit: https://techsource-inc.com/.

CONTACTS

Giordano Morichi
Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Srl
E: g.morichi@terrainnovatum.com
W: www.x-solo.com

Nicholas Hresko-Staab
Investor & Media Relations
Alliance Advisors IR
E: TerraIR@allianceadvisors.com

Curtis Christensen
SVP of Operations-West
TechSource
E: cchristensen@techsource-inc.com
W: www.techsource-inc.com

Carrie Holland
VP Marketing and Integrated Communications
TechSource
E: cholland@techsource-inc.com
W: www.techsource-inc.com

IMPORTANT INFORMATION FOR SHAREHOLDERS

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

In connection with the business combination, a Dutch public limited liability company (“Pubco”), GSR III Acquisition Corp. (“GSRT”) and Terra Innovatum s.r.l. (“Terra Innovatum” and, together with GSR III and Pubco, the “Registrant Parties”) have filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT’s ordinary shares in connection with GSRT’s solicitation of proxies for a vote by GSRT’s shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.

Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.

PARTICIPANTS IN THE SOLICITATION

Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

FORWARD LOOKING STATEMENTS

The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.

In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.

SOURCE: TERRA INNOVATUM SRL

View the original press release on ACCESS Newswire

NORTH YORK, ON / ACCESS Newswire / July 1, 2025 / ZTEST Electronics Inc. (“ZTEST” or the “Company“) (CSE:ZTE)(OTCID:ZTSTF) is pleased to announce that it will be moving from the OTC Pink Sheets to the newly established OTCID market on the OTC Markets Group platform effective July 1, 2025. The Company will continue to trade under the symbol ZTSTF.

The OTCID market requires enhanced reporting obligations, management certifications and company profile updates that give greater accountability and transparency for investors. The transition opens the door to a broader class of institutional and private investors who characteristically require rigorous reporting standards.

The stock will continue to trade without interruption, and no action is required from shareholders during this change.

About ZTEST Electronics Inc.
ZTEST Electronics Inc., through its wholly owned subsidiary Permatech Electronics Corporation (“Permatech”), offers Electronic Manufacturing Services (EMS) to a wide range of customers. Permatech’s offering includes Printed Circuit Board (PCB) Assembly, Materials Management and Testing services. Permatech operates from an ISO 9001:2015 certified facility in North York, Ontario, Canada. Permatech is a contract assembler of complex circuit boards, serving customers in the Medical, Power, Computer, Telecommunications, Wireless, Industrial, Trucking, Wearables and Consumer Electronics markets. It specializes in servicing customers who are looking for high yield and require high quality and rapid-turnaround on low and mid-volume production of high complexity products.

For more information contact: Steve Smith, CEO (604) 837-3751 email: steves@ztest.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR+ in Canada (available at www.sedarplus.com).

SOURCE: ZTEST Electronics Inc.

View the original press release on ACCESS Newswire

MONTREAL, QC / ACCESS Newswire / July 1, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a leading innovator in high-voltage electric marine propulsion systems, today announced it will host a live investor call and webcast to discuss the Company’s acquisition of Nautical Ventures Group Inc.(“Nautical Ventures, named the 2024 Boating Industry Top Dealer of the Year by Boating Industry.

Nautical Ventures has generated over US $100 million in annual revenue from 2020 to 2023, with a strong presence across Florida and national exposure through its boat show attendance, brand portfolio, and digital marketing platform. The acquisition represents a major milestone in Vision Marine’s growth strategy, providing access to a proven retail and service infrastructure and facilitating the market rollout of its E-Motion™ electric powertrain systems.

Event Details:

Wednesday, July 2, 2025, at 11:30 am ET / 8:30 am PT.

The Vision Marine conference call may be accessed as follows:

Webcast URL:

https://www.webcaster4.com/Webcast/Page/3129/52678

Teleconference:

Toll Free: 888-506-0062 International: 973-528-0011

Participant Access Code: 181749

Vision Marine’s management team plans to share insights into how this strategic move supports its broader vision for scaling electric propulsion in the recreational marine industry, enhances operational reach, and positions the Company for long-term growth.

About Vision Marine Technologies Inc.

Vision Marine Technologies Inc. (NASDAQ:VMAR) is a leading innovator in high-voltage electric propulsion systems for the recreational marine industry. The Company’s E-Motion™ powertrain offers OEMs and consumers a scalable, zero-emission, high-performance alternative to internal combustion systems. Vision Marine’s mission is to transform the boating experience through technology, efficiency, and integrated end-to-end electric solutions. Visit: www.visionmarinetechnologies.com

About Nautical Ventures Group, Inc.

Nautical Ventures is an award-winning marine dealership headquartered in Florida, operating nine retail and service locations with global reach. Known for its innovation and bold branding, the company offers a full portfolio of marine products-spanning powerboats, yachts, tenders, catamarans, and electric vessels-supported by factory-trained service and international export capabilities. Nautical Ventures leads the market in real-world adoption of electric propulsion and is the creator of the “Orange is the New Green” campaign. Visit: https://www.nauticalventures.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. securities laws, including statements related to the strategic, operational, and financial impacts of the acquisition. These statements are subject to risks and uncertainties, including those discussed in Vision Marine’s filings with the U.S. Securities and Exchange Commission. Vision Marine undertakes no obligation to update forward-looking statements except as required by law.

Investor Contact:
Bruce Nurse, Investor Relations
Vision Marine Technologies Inc.
(303) 919-2913
bn@v-mti.com

SOURCE: Vision Marine Technologies Inc

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with advancing its lead candidate NV-387 into Phase II clinical drug development.

NanoViricides has chosen MPox as the first indication to advance NV-387 into Phase II clinical trials out of the four indications for which the Company has substantial efficacy data in animal studies, namely RSV, Influenza, COVID, and Orthopoxviruses (MPox/Smallpox).

The MPox program enables advancing its pipeline towards revenue in the fastest possible manner, the Company believes. The Company intends to advance NV-387 against respiratory infections soon after the Phase II clinical trial of NV-387 for the treatment of MPox infection gets under way.

NanoViricides has already added one Clinical trial Site to the MPox Phase II Program.

A Phase II Clinical Trial Protocol has been developed with the Principal Investigator at this site in the Democratic Republic of Congo (DRC), and this Protocol is undergoing final refinements.

A Clinical Trial Application is in development with many parts having been substantially completed.

NanoViricides has engaged a Clinical Research Organization (CRO) to organize and conduct this Phase II clinical trial for the treatment of MPox with NV-387, as previously stated, and this CRO has organized the Clinical Trial Site and is preparing the CTA with the Company’s inputs.

The manufacture of the drug substance NV-387 is substantially completed at the Company’s own facility. The manufacture of the drug product “NV-387 Oral Gummies” is in progress.

MPox as the first indication has several strategic benefits for the Company.

Firstly, because of the continuing epidemic in the African Region there is a strong need for the drug and also there is the ability to recruit patients and complete the clinical trial in a timely manner. Additionally, running clinical trials in the African Region is substantially less expensive than clinical trials in USA or Europe that the Company has planned for RSV, a commercially important indication with multi-billion dollar potential market.

Secondly, a proof of efficacy in humans of NV-387 against MPox would validate our use of lethal challenge animal models and would establish that our animal model data are predictive of human outcomes. This would have huge implications since our animal model data against every infection we have tested to date has demonstrated NV-387 to be substantially superior to existing drugs, viz. RSV, Influenza, COVID, and of course, MPox/Smallpox.

Thirdly, there is a strong financial case for choosing MPox as the indication. This business case has become even stronger with the failure of tecovirimat (Tpoxx) in clinical trial against MPox. Tecovirimat and brincidofovir (Tembexa) are the only two drugs approved by the US FDA for the treatment of Smallpox, a virus of bioterrorism concern. Both of these drugs were approved under the “FDA Animal Rule”, which eliminates the need for demonstration of efficacy in humans. The “FDA Animal Rule” is applicable for diseases such as Smallpox and others where clinical trials in human patients are not feasible or would be unethical.

These FDA approvals have led to the acquisition of these two drugs into the US Strategic National Stockpile (SNS) to the tune of billions of dollars. And now, there is a clear need for replacing these non-performing drugs with a drug that actually works against MPox and Smallpox (see further down below).

We believe NV-387 would become the choice for addition to the SNS if our proposed Phase II clinical trial against MPox demonstrates benefits of the NV-387 treatment.

The most recent acquisition contracts with BARDA for tecovirimat, which were for drug replenishments, have been valued at over $150million.

An initial stocking contract for NV-387 is likely to be substantially larger, as was the case with the initial acquisition of several drugs into the SNS.

Brincidofovir failed an early clinical trial against MPox due to liver toxicity. Tecovirimat failed a recent clinical trial against MPox since it demonstrated no superiority in efficacy over the standard of care.

Importantly, both of these drug candidates are small chemicals that the viruses can readily escape by mutations. Smallpox, if it ever becomes fielded as a bio-terrorism agent, is unlikely to be in the “original” form of the virus, and could be explicitly manipulated to breed resistance to such small chemical drugs by onerous entities.

Of note, MPox is in the same family as the Smallpox virus; MPox causes a much weaker form of disease than the Smallpox virus.

Thus there is a strong case for HHS to support NV-387 drug development for Bioterrorism Readiness.

The “NV-387 Oral Gummies” drug product is a soft solid formulation that is designed to stick in the oral cavity and dissolve naturally over time, with no solid object (pill or capsule) swallowing necessary. This is important for MPox because MPox causes lesions on mucosal surfaces that make swallowing painful and difficult. MPox is primarily known for the explicit characteristic painful rash on the external skin, but it is a significantly more severe disease than just a skin rash.

The MPox virus circulating in DRC and neighboring regions is of Clade 1a and Clade 1b subtypes, with the latter predominant. Clade 1b is more transmissible of the two, which is why it has resulted in a sustained epidemic. The MPox Clade 1a case fatality rate (CFR) is about 3%-11% whereas the CFR for Clade 1b is about 1%. The MPox Clade 2b is the virus causing continuing cases in the Western world, which causes a much less severe disease than Clade 1a/1b and has a very low CFR, according to CDC. Sporadic cases of Clade 1 in the Western world continue to occur. Four separate travel-related MPox Clade 1 cases reported in the USA that did not result in any further spread, since November 2024, according to the CDC ( https://www.cdc.gov/mpox/situation-summary/index.html ). Clearly, the threat of MPox Clade 1 causing a potential epidemic in the USA cannot be ignored, and readiness with a drug that works against the same is important to achieve.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

ISTANBUL, TR / ACCESS Newswire / June 30, 2025 / Aesthetic operations significantly influence self-confidence and quality of life in today’s environment, when beauty is increasingly individual and comprehensive. Doku Clinic, located in the center of Istanbul, is one of the top institutes in this discipline. The clinic has grown in popularity among patients from all over the world who are looking for exceptional outcomes in body and nose aesthetics because to its skilled staff, cutting-edge equipment, and personalized approach.

Why is Doku Clinic So Popular?

The world-renown of Doku Clinic is due to the direction of two famous doctors:

• Dr. Engin Öcal is a renowned specialist in cosmetic and plastic surgery, particularly in the areas of body contouring and breast augmentation.

• Dr. Serhan Derin is an expert in rhinoplasty surgery and finds the sweet spot between the nose’s aesthetics and its functionality.

The individualized care that patients receive at Doku Clinic is what makes it stand out. Anatomical details, skin type, and aesthetic objectives inform the development of individualized treatment programs for each patient. Every time, you can count on enduring, harmonic, and all-natural results.

Dr. Engin Öcal: A Master of Precision in Shaping Beauty

Breast augmentation, liposuction, stomach tucks (abdominoplasty), and Brazilian butt lifts (BBLs) are just a few of the popular cosmetic operations that improve patients’ physical appearance and sense of self-worth.

With each metamorphosis, Dr. Engin Öcal infuses a creative vision with therapeutic accuracy. Patients who want a natural look that complements their body proportions have come to trust Doku Clinic because of his approach to breast augmentation Turkey.

To guarantee maximum satisfaction, minimal scarring, and quick recovery, Dr. Öcal takes into account each patient’s unique anatomy and lifestyle when choosing implant size, shape, and placement. Restoring one’s femininity and self-esteem are important goals for many people undergoing the operation.

Dr. Serhan Derin’s Functional Beauty Program

Rhinoplasty, which aims to restore nasal airflow while simultaneously improving the patient’s face features, is one of the most intricate and life-altering cosmetic procedures. Renowned for his skill in customizing each nose surgery to match each patient’s unique face anatomy and medical requirements, Dr. Serhan Derin is a frontrunner in this profession.

No matter the kind of rhinoplasty-primary, revision, or ethnic-Dr. Derin always aims to create delicate, natural-looking noses that complement the patient’s overall characteristics. Simultaneously, he fixes any respiratory problems, which greatly enhances quality of life.

His dedication to natural aesthetics and individualized care is right on trend with the current movement away from “overdone” outcomes and toward embracing one’s own unique beauty.

What Made Amanda Du Pont, Alessia Spagnulo, and Priscila Da Silva Choose Doku Clinic for Their Breast Aesthetics? A Global Trust-Building Story

The worldwide influencers who candidly document their beauty adventures on social media have contributed to the growing international prominence of Doku Clinic. These women, who have millions of followers, opted for a single, game-changing operation at Doku Clinic.

Amanda Du Pont, a content producer and actress from South Africa, traveled all the way to Istanbul to have Doku Clinic implant natural breast implants. She was very complimentary of the clinic’s welcoming atmosphere, the exceptional quality of service, and the organic outcomes that Dr. Engin Öcal had accomplished. In an honest review, Amanda praised Doku Clinic and encouraged her followers to make an informed decision.

Italian fashion influencer Alessia Spagnulo has decided to have breast implants at Doku Clinic after much deliberation. Following the treatment, she enthusiastically recounted how it boosted her self-esteem and physical attractiveness. In particular, she lauded the individualized attention and the flattering effect on her figure.

In order to get a more harmonious body type, fitness and lifestyle blogger Priscila Da Silva had breast implants in Turkey. From the initial consultation before the procedure to the healing process, she wrote about how pleasant and reassuring the entire experience was. Doku Clinic, she said, “makes you feel reborn.”

Transforming Your Look Without Incisions: Experience at the Doku Clinic

For people from across the world seeking a unique medical tourism experience, Doku Clinic is more than just a place to get medical treatments done. Airport transportation, hotel stays, translation assistance, pre- and post-operative consultations, and individualized follow-ups are all part of their VIP service packages.

The cutting-edge operating rooms of Doku Clinic prioritize cleanliness and patient safety, and they have received approval from the Ministry of Health to conduct all surgical procedures. Regular check-ins and medical advice ensure that patients are properly followed throughout their recovery process.

Elegance and Self-Assurance, Harmoniously Satisfied

Restoring self-esteem and confidence are two of the many benefits of cosmetic surgery, which goes beyond only improving one’s physical look. Patients are more than simply another number at Doku Clinic; they are companions on a path to healing and personal growth.

Science, artistry, and ethical care come together at Doku Clinic, where patients may have a variety of cosmetic procedures such as breast augmentation, rhinoplasty, body contouring, and non-surgical skin treatments.

Finally, Istanbul’s Most Reliable Spot for Travelers Seeking Beauty

The cosmetic makeover you seek may begin at Doku Clinic if you are seeking natural, balanced, and long-lasting results. As a frontrunner in aesthetic innovation, the clinic has achieved global success in breast aesthetics, achieved technical mastery in nose surgery, and provides an unsurpassed patient experience.

Ready to start your aesthetic journey?

Meet Doku Clinic-where beauty and confidence meet.

Media Contact: Doku Clinic
Email: info@dokuclinic.com
Phone: +90 555 140 04 04
Website: https://www.dokuclinic.com/en
Address: Merkez Mah. İstiklal Sok. No:9 Şişli, İstanbul/Türkiye

SOURCE: Doku Clinic

View the original press release on ACCESS Newswire

By Ovais Riaz & Waa Say – Team Editorial Evrima Chicago

BIRMINGHAM, GB / ACCESS Newswire / June 30, 2025 / The Silent Crisis of Disappearing Languages

In our increasingly globalized world, UNESCO warns that nearly half of all spoken languages are currently endangered, with one disappearing every two weeks. Against this sobering backdrop, educator and author Divya Mistry-Patel has emerged as a passionate advocate for linguistic preservation through her groundbreaking work in children’s literature.

Mistry-Patel is an educator, entrepreneur, and celebrated children’s book author. She has taken a bold step toward making bilingual learning both accessible and engaging.

A Personal Journey Becomes a Cultural Mission

Born into a multicultural Gujarati family in the UK, Mistry-Patel experienced firsthand the gradual erosion of heritage languages in diaspora communities.

“I watched cousins who could understand Gujarati but couldn’t speak it, and eventually children who couldn’t even understand,” she recalls.

This personal observation sparked what would become her life’s work-creating tools to make language learning accessible, engaging, and intergenerational.

Her latest creation, Mari Rang Be Range Biladi (translated as “My Colourful Cat”), represents far more than just another bilingual picture book. It’s a comprehensive language-learning system that includes:

• Dual-language storytelling with culturally rich narratives

• Gujarati alphabet introduction with phonetic guides

• Comprehension exercises designed for family participation

• QR-code linked audiobook for proper pronunciation

• Full English translation for non-Gujarati-speaking parents

• Opportunities to see that diversity is to be celebrated and beauty is within us all

The Growing Demand for Multilingual Education

Recent studies from the University of Chicago demonstrate that bilingual children develop stronger executive function skills, showing 20% greater cognitive flexibility than monolingual peers.

Yet despite these proven benefits, the publishing industry has been slow to respond. A 2022 survey by the Cooperative Children’s Book Center revealed that while 33% of U.S. children come from bilingual homes, only 12% of children’s books published that year offered any non-English content. In the UK, around 20% of children speak or understand more than one language. Furthermore, around half of the world’s population speaks two or more languages.

Mistry-Patel has positioned herself at the forefront of changing this disparity.

“This isn’t just about language retention,” she explains. “It’s about giving children the tools to navigate their multicultural identities with confidence.”

Breaking Barriers in Publishing

The path to bringing Mari Rang Be Range Biladi to market reveals systemic challenges in the publishing industry. Major retailers often relegate bilingual books to “special interest” sections-when they carry them at all. Traditional publishers frequently reject bilingual manuscripts, citing “limited market potential.”

Yet professionals continue to emphasize the importance of encouraging parents to speak in their mother tongue with their children. Research has shown the benefits of bilingual learners, yet this is not reflected on our bookshelves.

In a world where native languages are slowly fading from everyday use, Mistry-Patel is on a mission to ensure cultural heritage and linguistic roots are preserved.

Undeterred, she adopted an innovative hybrid approach:

• Self-publishing to maintain creative control and raise awareness

• Partnering with educational institutions for distribution

• Developing teacher resources to encourage classroom adoption

• Leveraging social media to build direct community support

This strategy has yielded impressive results, with the book gaining traction in both educational circles and Gujarati communities worldwide.

Recognition and Future Horizons

The impact of Mistry-Patel’s work is gaining institutional recognition. She currently holds nominations for:

• Kent Women in Business Awards 2025 (Runner-Up in Innovation Award & Finalist in Women In Education Award)

• The Tutors’ Association Awards (Shortlisted in two categories: Education Resources for Tuition 2025 and Tuition Partner of the Year 2025)

• The Diversity Book Awards (shortlist announcement imminent)

Through her company, Academic Achievements Ltd, she is now developing versions in Punjabi, Hindi, Malayalam, and Tamil-potentially reaching over 500 million native speakers globally.

A recent partnership with local schools and Kent libraries has made the book freely available to local families, with plans for similar initiatives nationwide.

How Readers Can Support the Movement

Mistry-Patel emphasizes that preserving linguistic diversity requires a community effort:

• Request bilingual books at local bookstores and libraries

• Share experiences using #MotherTongueMatters

• Engage with content on Instagram and Facebook

• Participate in virtual reading events

• Gift bilingual books for birthdays and holidays

• Read to your children or listen to audiobooks together

The Ripple Effect of Language Preservation

As linguist Dr. Ananya Sharma notes,

“When we lose a language, we don’t just lose words-we lose entire ways of seeing the world.”

Mistry-Patel’s work represents a vital countercurrent to this loss, creating what educators are calling “the building blocks of cultural continuity.”

With Mari Rang Be Range Biladi available on Amazon and her expanding series underway, Mistry-Patel is proving that one passionate voice can indeed change the narrative-in any language.

Mistry-Patel has more books coming soon in both South Asian languages and in English. The books are all designed to empower young minds and encourage their love for learning. Through Mistry-Patel’s experience in the education sector, her experience over the years has allowed her to create resources with neurodivergent students in mind. Keep up-to-date with the latest resources, services and books created by Academic Achievements Ltd on their socials.

Connect with the Movement

Platform	Details
Website	www.academicachievements.co.uk
Instagram	@academicachievementsltd,@author_divyamistrypatel
Facebook	Academic Achievements
Educational Inquiries	help@academicachievements.co.uk info@academicachievements.co.uk

Disclaimer

This article was authored, developed, and distributed by Evrima Chicago, LLC, serving as the official editorial and media representative for Divya Mistry-Patel, founder of Academic Achievements Ltd and author of Mari Rang Be Range Biladi. This content is released for educational, cultural, and journalistic purposes.

• Evrima Chicago officially represents Divya Mistry-Patel for all media, publicity, and syndication matters related to this article and affiliated literary works.

• The views, insights, and commentary expressed herein are based on interviews, verified statements, and publicly available materials, and reflect the intent to inform and inspire discourse on bilingual education and cultural preservation.

• This article is not legal advice, nor does it reflect the views of any government agency or institutional partner mentioned.

• All statistics, studies, and expert quotes referenced are cited in the Sources & Citations section at the end of this publication.

• Reproduction, excerpting, or redistribution of this content must credit both the author and Evrima Chicago, LLC as the originating editorial source.

• Educators, community leaders, librarians, and institutions are encouraged to use this article as part of broader conversations on multilingualism, diversity, and inclusive learning.

Media & PR Contact

Dan Wasserman
Head of Media & Public Affairs
PR@EvrimaChicago.com
+1 (909) 326-0347
Evrima Chicago – Editorial Syndication Bureau

Sources & Citations

Source	Details
UNESCO Language Endangerment Report	https://www.unesco.org/en/days/mother-language
University of Chicago Study on Bilingualism	Bialystok, E., & Barac, R. (2012). Executive Function and Cognitive Flexibility in Bilingual Children
Cooperative Children’s Book Center 2022 Report	https://ccbc.education.wisc.edu/literature-resources/ccbc-diversity-statistics/
UK Gov Report on Children’s Language Usage	Department for Education, UK (2020)
Dr. Ananya Sharma Quote	Language and Identity Studies, Delhi University Symposium, 2023

SOURCE: Evrima Chicago LLC.

View the original press release on ACCESS Newswire